Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Technology appraisal guidance
Reference number: TA628
Published:
The company who produces lorlatinib, Pfizer, has requested more time to allow additional data to be included in the submission. As a consequence, the first committee meeting discussion has been moved to 16 April 2019.